A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
|Videos|July 12, 2022
A Talk with Albert Yan, MD on Current Trends in Technology
Author(s)Lois Levine, Correspondent
At the SPD 2022 47th Annual Meeting, we chat with Albert Yan, MD, of Children's Hospital of Philadelphia on the latest trends in technology for pediatric dermatologists.
Advertisement
Albert Yan, MD, professor of Pediatrics and Dermatology at the Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, also a past president of the Society for Pediatric Dermatology, shares highlights of his fascinating presentation on how pediatric dermatology is benefiting from technologies that include crowdsourcing, artificial intelligence and machine learning, and no-code and low-code software building platforms.
Advertisement
Related to this article
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Advertisement
Advertisement
Trending on Dermatology Times
1
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
2
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
5